cd30-car t cells
Cell therapyexperimental
Clinical trial activity
14 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Oct 3, 2011 (NCT01316146)
Timeline
Indications
Studied for
- Enteropathy-Associated T-Cell Lymphoma · Phase 1
- Hodgkin Disease · Phase 1
- Immune System Diseases · Phase 1/Phase 2
- Immunoproliferative Disorders · Phase 1/Phase 2
- Leukemia · Phase 1/Phase 2
- Leukemia-Lymphoma, Adult T-Cell · Phase 1
- Lymphatic Diseases · Phase 1/Phase 2
- Lymphoma · Phase 1/Phase 2
- Lymphoma, Extranodal NK-T-Cell · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Large-Cell, Anaplastic · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Lymphoma, T-Cell · Phase 1
- Lymphoma, T-Cell, Cutaneous · Phase 1
- Lymphoma, T-Cell, Peripheral · Phase 2
- Lymphomatoid Papulosis · Phase 1
- Lymphoproliferative Disorders · Phase 1/Phase 2
- Mycosis Fungoides · Phase 1
- Neoplasms · Phase 1/Phase 2
- Neoplasms by Histologic Type · Phase 1/Phase 2
- Neoplasms, Germ Cell and Embryonal · Phase 2
- Sezary Syndrome · Phase 1
Mechanism of action
- Tumor necrosis factor receptor superfamily member 8Immunity, passive
TNFRSF8 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- altcar.cd30 cells
- anti-cd30-car t cells
- anti-cd30-car-t cells
- atlcar.cd30.ccr4 cells
- atlcar.cd30 cells
- car.cd30 t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06519344 | Early Phase 1 (Phase 1) | Jul 31, 2024 | Huazhong University of Science and Technology |
| NCT06756321 | Early Phase 1 (Phase 1) | Sep 18, 2023 | Government of China, Nantong University |
| NCT06532643 | Early Phase 1 (Phase 1) | Aug 24, 2023 | Anhui Medical University, Government of China |
| NCT05634785 | Phase 2 | Dec 9, 2022 | University of North Carolina at Chapel Hill |
| NCT04083495 | Phase 2 | Sep 17, 2019 | University of North Carolina at Chapel Hill |
| NCT04008394 | Phase 1 | Jul 1, 2019 | Huazhong University of Science and Technology, Wuhan Bio-Raid Biotechnology Co, Ltd. China |
| NCT03602157 | Phase 1 | Oct 30, 2018 | University of North Carolina at Chapel Hill |
| NCT03049449 | Phase 1 | Mar 17, 2017 | National Cancer Institute (NCI) |
| NCT02958410 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2016 | People's Liberation Army of China |
| NCT02690545 | Phase 1/Phase 2 (Phase 2) | Jun 28, 2016 | University of North Carolina at Chapel Hill |
| NCT02663297 | Phase 1 | May 25, 2016 | National Heart, Lung, and Blood Institute (NHLBI), University of North Carolina at Chapel Hill |
| NCT02274584 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2014 | Peking University, University of Florida |
| NCT01316146 | Phase 1 | Oct 3, 2011 | Baylor University, Methodist Cancer Center, Houston, Texas, University of North Carolina at Chapel Hill |
| NCT03914885 | N/A | — | University of North Carolina at Chapel Hill |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of North Carolina at Chapel Hill | Academic/Hospital | 7 | 7 | 3 | 2011 |
| Government of China | Government | 2 | 1 | 1 | 2023 |
| Huazhong University of Science and Technology | Academic/Hospital | 2 | 2 | 1 | 2019 |
| Anhui Medical University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Baylor University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Nantong University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2017 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2016 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2016 |
| University of Florida | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Wuhan Bio-Raid Biotechnology Co, Ltd. China | Government | 1 | 0 | 1 | 2019 |
13 organizations
Page 1 / 1